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Challenges to Unravel Mechanisms 
of GERD
Shouji Shimoyama
Abstract
Gastroesophageal reflux disease (GERD) encompasses a spectrum of disorders 
caused by a reflux of gastric contents into the esophagus or complications of 
gastroesophageal reflux. Although depending on the definition, the prevalence of 
GERD is higher in the West than in the East, and the prevalence has been slightly 
increasing, so that the clinicians, even though they are not gastroenterologists, must 
encounter GERD patients and treat them. However, the clinicians do feel difficulty 
in treating GERD patients, since prescription of acid neutralizing agents, such as 
proton pump inhibitors (PPIs), sometimes fail to resolve their complaints. This may 
be partly explained by the discrepancies between clinical complaint and endoscopic 
findings; some patients present endoscopic esophagitis while some do not, and be 
partly explained by the potentially wide spectrum of pathophysiological etiologies 
than has been thought. This chapter describes current knowledge on heterogeneous 
mechanisms of GERD development. Clarifying the mechanisms of GERD on the 
individual basis may realize conceptual shift from uniform prescription of acid 
neutralizing agents to establishment of patient-oriented therapies.
Keywords: gastroesophageal reflux disease, nonerosive reflux disease, esophagitis, 
reflux hypersensitivity, functional heartburn, central sensitization, proton pump 
inhibitors
1. Introduction
Gastroesophageal reflux disease (GERD) is defined as a condition with at least 
weekly troublesome symptoms due to the abnormal reflux of stomach contents 
into the esophagus [1]. Heartburn and/or acid regurgitation are ranked 7th on the 
list prompting visits to doctors, and GERD is the most common diagnosis given 
in outpatient visits [2]. GERD appears worldwide with some geographic varia-
tion. Prevalence estimates are 18–28% in North and South America, 9–33% in the 
Middle East, 12% in Australia, but less than 10% in East Asia [3]. In addition, an 
analysis of temporal trends suggests a particular increase in GERD prevalence in 
North America and Europe [4], while such a trend in Asia is indeterminable [4–6], 
partly due to the regional variation of prevalence being much higher in Southwest 
and Western Asia than in Eastern Asia [6]. In Japan, the prevalence of GERD was 
below 10% in the 1980s but has shown a two- or three-fold increase in the twenty-
first century [7]. Although such time-trends or steady increases in the rise in the 
number of patients might be attributable to an increased awareness of the disease, 
and the prevalence of GERD varies between studies, the worldwide disease burden 
confirms that the numbers of patients suffering from GERD is substantial. Since 
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the symptoms do compromise patient quality of life (QOL) [8], clinicians, even if 
they are not gastroenterologists, may frequently encounter such patients and should 
treat them.
Acid-suppressing agents, such as proton pump inhibitors (PPIs), are a main 
choice of medication [9]; however, it is also true that while most patients do respond 
it, some do not. A recent study of PPI use has demonstrated that 20–26% of GERD 
patients showed persistent heartburn of any intensity for 2 or 3 days or more per 
week [10]. Recent systematic reviews found that 17–45% of GERD patients experi-
enced persistent troublesome heartburn or regurgitation despite PPI therapy [11, 
12]. That not all GERD patients can attain complete relief of GERD symptoms sug-
gests that GERD is likely to be a heterogeneous disease entity which may explain the 
above unmet clinical needs. In light of the fact that patient QOL deteriorates by PPI 
refractoriness [13] as well as GERD symptoms per se, even if persistent symptoms 
are mild [14], clarifying the mechanisms of GERD or PPI refractoriness enables 
clinicians to prescribe medications according to the underlying mechanism on a 
patient-by-patient basis, which subsequently realizes clinical improvement.
This chapter discusses the current knowledge on the underlying mechanisms 
of PPI refractory GERD, and considers potential research directions attempting to 
resolve its symptoms, especially those among PPI refractory patients.
2.  Reflux symptoms do not necessarily coincide with endoscopic 
findings
One of the complex phenomena that impedes the understanding of GERD is that 
reflux symptoms, endoscopic findings, and treatment results do not necessarily coin-
cide with each other, despite the fact that GERD symptoms are by definition caused 
by the abnormal reflux of gastric contents into the esophagus. GERD is divided into 
reflux esophagitis and nonerosive reflux disease (NERD), which is a condition of 
reflux symptoms with no endoscopically apparent damage to the esophageal mucosa. 
A substantial proportion (50–70%) of GERD patients demonstrates endoscopi-
cally negative findings [15, 16], suggesting that NERD forms the main body of 
GERD. Curiously, endoscopic healing of erosive esophagitis does not necessarily 
result in symptom relief. In the same sense, a novel potassium-competitive acid 
blocker, vonoprazan, achieved improvement of heartburn in only approximately 
20% of NERD patients [17]. These results suggest that the association of esophageal 
acid exposure with patient symptoms is tenuous in a certain fraction of GERD 
patients. On the other hand, some patients with endoscopically confirmed esopha-
gitis are asymptomatic. Consequently, the prevalence and treatment success rate of 
GERD are greatly influenced by its definition, i.e., whether or not the study body 
includes NERD patients, whether or not it includes asymptomatic erosive reflux 
esophagitis patients, and whether or not treatment success includes only complete 
symptom relief or extends an even partial response.
3. Mechanisms
3.1 Conventional theory: acid as a direct contributor
Traditionally, reflux esophagitis is thought to be a condition resulting from a 
caustic, chemical injury inflicted by refluxate components such as hydrogen ions and 
pepsin. Hydrogen ions injure the superficial layer of the esophageal mucosa and cause 
esophagitis, and pepsin destroys the tight junction of the esophageal epithelium. 
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These chemical injuries lead to dilatation of the intracellular spaces (DIS) and an 
increase in paracellular permeability, which eventually allows acid to penetrate into 
deep layers of the esophagus, followed by the attraction of inflammatory cells, and 
finally stimulates nocireceptors [18]. In this theory, the epithelial injury triggers the 
pathophysiological cascade of GERD, beginning at the luminal surface of the esopha-
geal epithelium, and then proceeds to the deeper layer. This mechanism is readily 
plausible for GERD patients with esophagitis; however, acid penetration through DIS 
as a main causative mechanism of GERD cannot explain why PPI refractory patients 
still exist as do symptomatic patients without esophagitis.
3.2 New theory: GERD is an immune mediated injury
On the other hand, the literature contains some experimental data which cannot 
necessarily be explained by the conventional theory, namely, acid penetration 
through DIS as a cause of GERD. In a rat reflux esophagitis model, inflammatory 
cells appeared at the deep layer of the epithelium, and then infiltrated upward to 
the superficial layer of the esophagus [19]. Basal cell and papillary hyperplasia pre-
ceded the development of esophagitis [19]. Consistent results were demonstrated in 
a human study, where stopping the PPI therapy in successfully PPI treated patients 
was associated with T-lymphocyte infiltration in the deep layer of the esophagus as 
well as basal cell and papillary hyperplasia without apparent surface erosions [20]. 
Degrees of DIS in patients with reflux esophagitis or NERD did not differ from 
those of asymptomatic healthy volunteers [21].
Evidence has been accumulated that pro-inflammatory cytokine release from 
esophageal epithelium, mesenchymal cells, and endothelial cells is an initial event 
of GERD. The participants of pro-inflammatory cytokines are interleukin (IL)-8 
[19, 22, 23], IL-1 beta [19, 23], monocyte chemoattractant protein 1 (MCP-1) [24], 
IL-6 [25], IL-33 [26], tumor necrosis factor (TNF)-alpha [27], prostaglandin E2 
[28, 29], hypoxia inducible factor (HIF)-2alpha [30], and platelet activating factor 
(PAF) [31, 32]. These pro-inflammatory cytokines attract immune cells—lympho-
cytes and polymorphonuclear cells—into the esophageal mucosa and submucosa. 
Interestingly, antineutrophil serum was found to inhibit inflammatory markers in 
rat acute esophagitis [33].
Another source of pro-inflammatory cytokines is the proteinase-activated 
receptor 2 (PAR2) localized on the surface of epithelial cells. PAR2 is activated by 
trypsin and weak acid, then stimulates pro-inflammatory cytokine release such 
as IL-8 from the epithelial cells, induces a neuroinflammatory effect mediated by 
neurotransmitters such as substance P and calcitonin gene-related peptide (CGRP), 
and subsequently establishes visceral hypersensitivity [34]. Indeed, PAR2 expression 
increases in patients with erosive esophagitis as well as NERD [34]. PAR2 activation 
has been correlated with IL-8 expression and further with DIS, papillary hyperpla-
sia, and intraepithelial lymphocyte density [34]. These mechanisms mediated by 
pro-inflammatory cytokines would partly explain why PPI solely cannot necessarily 
resolve GERD symptoms and why a protease inhibitor, i.e., camostat mesilate, is 
effective in patients in whom GERD symptoms are caused by weakly acidic episodes.
Weak acid activates acid-sensing nocireceptors such as the transient receptor 
potential channel vanilloid subfamily receptor-1 (TRPV-1) [35, 36] and acid-
sensing ion channels (ASIC) [37]. TRPV-1 is also activated by pro-inflammatory 
cytokines. TRPV-1 is a detector of various noxious stimuli including heat, acid, 
and irritant pollutants [38, 39]; it thus has been recognized as an initial molecule 
of nociceptive transmission. Once activated, neurotransmitters such as substance 
P and CGRP are released, afferent neurons evoke a sensation of burning pain, and 
finally peripheral and central sensitization is established. The activation of TRPV-1 
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also produces PAF [31] and adenosine triphosphate (ATP) [40], the former acting 
as a chemoattractant of inflammatory cells [41], while the latter stimulates both 
substance P and CGRP release from esophageal submucosal neurons [40] as well as 
the secretion of pro-inflammatory cytokines at the esophageal epithelium [35]. ATP 
per se is also a neurotransmitter [42] involved in the sensation of pain. Interestingly, 
an increased expression of TRPV-1 was observed not only in erosive esophagitis but 
also in NERD patients without correlation with acid exposure [43].
Taking all these processes into account, while not fully elucidated, it is conceiv-
able that the secretion of pro-inflammatory cytokines, decreased mucosal integrity, 
exposure of subepithelial nerves to acid, and neuropeptide release to transmit noci-
ceptive stimuli through the peripheral nerve to the brain may interplay to manifest 
GERD symptoms. Once such a network operates, patients have a lower threshold for 
pain perception by chemical or mechanical stimulation. The above findings support 
the hypothesis that an immune mediated neuroinflammatory cascade may underlie 
the development of GERD symptoms, and that GERD is an immune mediated 
injury rather than a chemical burn. This hypothesis considers that the secretion of 
pro-inflammatory cytokines is an initial event, the release of a variety of media-
tors is the second, and then the transmission of pain through the peripheral nerve 
to the central nervous system is the last step of the cascade. This cascade contrasts 
sharply with the conventional theory in which caustic acid-induced direct epithelial 
injury is an initial event of GERD; it could explain why not all GERD symptoms 
can be regulated solely by acid suppression. This is an essential background to the 
clinically reiterating and troublesome claim that there is a distinction between 
endoscopically-based and symptom-based GERD diagnosis.
4.  PPI-refractory GERD comprises heterogeneous pathophysiological 
conditions
Under the above new theory, the primary focus should be on which factors switch 
on the cascade. The advent of multichannel intraluminal impedance-pH monitoring 
enables us to count the number of reflux events, to measure acidity of reflux content, 
and to differentiate between liquid and air in a refluxate. This technique clarifies that 
the initial event that triggers the cascade at the esophagus is not only acid exposure 
but also weak acid or weak alkaline conditions, temperature, electrical stimuli, and 
mechanical stimuli [44–48]. More detailed analyses of content and pH in the reflux-
ate as well as degrees of symptom-reflux association create challenges to classify 
PPI-refractory GERD into three subcategories: (1) true GERD, in which symptoms 
are associated with acid reflux but acid neutralization is incomplete; (2) reflux 
hypersensitivity, where symptoms are associated with nonacid reflux; and (3) func-
tional heartburn, where symptoms are exerted by nonacid and nonreflux events. The 
second and third subcategories could be putative factors that are responsible for PPI 
refractoriness or symptomatic NERD (Figure 1). Recently, the Rome IV classifica-
tion [49] involves these mechanisms as underlying mechanisms of PPI-refractory 
GERD that allows a paradigm change for understanding this condition.
Reflux hypersensitivity is a heightened perception of physiological reflux which 
results in persistent GERD symptoms despite PPI therapy [44]. This is characterized 
by normal acid exposure in the distal esophagus but symptoms are attributable to 
reflux. On the other hand, functional heartburn is distinct from reflux hypersensitiv-
ity, in that functional heartburn is characterized by normal acid exposure in the distal 
esophagus without any apparent symptom-reflux association. That baseline imped-
ance was reduced in erosive gastritis and acid-associated GERD but not in functional 
heartburn suggests that functional heartburn is caused by factors other than acid [50].
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In this regard, peripheral and central sensitization has recently provided insight 
into mechanisms establishing of esophageal perception and symptom exacerbation 
unrelated to acid reflux. Peripheral neuron stimuli triggers repeated neurotransmit-
ter release, and repetitive peripheral firing causes increased excitability of afferent 
nerves that could establish central sensitization [51]. The upregulated nociceptive 
pathways could lower resting esophageal pain thresholds, resulting in amplified 
responses to painful stimuli (hyperalgesia), or resulting in pain perception to non-
painful stimuli (allodynia). In this condition, minor physiological noxious stimuli 
or even innocuous stimuli can be interpreted by the patient as a major symptom, 
and once hypersensitivity is established, it could continue to potentiate pain even 
after the stimuli is discontinued, thus “acid” would no longer be a major cause.
In this context, psychiatric comorbidity or psychological stressors could 
be causes of, or amplifying factors of peripheral and central sensitization. 
Psychological distress [52], anxiety [53], depression [53], poor sleep quality 
[54–57], decreased general well-being [58–60], and environmental stress [61] are 
associated with PPI-refractory GERD. The improvement of reflux symptoms by 
interventions aimed at reducing stress suggests that the brain-gut interaction and 
cerebral processing [62] might be responsible for this condition. These psychologi-
cal factors may compromise esophageal motor function by affecting the enteric 
nervous system and can modulate esophageal perception, making patients pay 
excessive attention to intraesophageal events, and consequently cause percep-
tion and interpretation of these esophageal events as painful (hypervigilance). 
By contrast, however, several studies have failed to demonstrate such interaction. 
Psychological distress was not associated with treatment failure [63]. The relative 
risk of anxiety or depression in PPI failure was minimal, with the odds ratio being 
1.15 [64]. The plausible explanations for these inconsistent results are that the 
degrees of influence on the enteric nervous system are different between patients 
Figure 1. 
The acidity of refluxate is associated with probability of PPI response. The higher probability of PPI 
refractoriness is ascribed to the conditions that factors other than acid are more predominant. The possibilities 
of reflux hypersensitivity and functional heartburn are more increased according to the less roles of acid.
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even under the same psychiatric stress. Alternatively, the difference in psychiatric 
medication given to each patient may play a role. Undoubtedly, the manifestation of 
GERD symptoms due to a greater psychiatric background should be more likely to 
be approached by psychotherapy.
This subclassification is clinically important in that true GERD is expected to 
respond to enhanced or double dose PPI therapy or be a candidate for antireflux 
surgery, while reflux hypersensitivity and functional heartburn are assumed to 
show scant response to it. Therefore, it is important to clarify the weight of each 
component and dominancy in the PPI refractory patients. In a study of 329 NERD 
patients, 40% showed abnormal acid exposure (true GERD), 36% had reflux 
hypersensitivity, and 24% had functional heartburn [65]. Another study demon-
strated that 40% of 171 symptoms in the PPI refractory GERD patients were consid-
ered reflux hypersensitivity, while acid related GERD was only 4.7% [66]. A recent 
study to explore the composition of 4296 reflux events in 78 PPI refractory patients 
elucidated that reflux contents are heterogeneous: 24% of reflux events were caused 
by gas, and 55% of patients were nonacid and reflux unrelated [67]. Finally, as 
many as 58% of GERD symptoms or 52% of PPI-refractory GERD patients fall into 
the functional heartburn category [68, 69].
Perhaps background causative factors are mixed, and the extent to which each 
factor contributes to PPI-refractory GERD is different between patients. Those who 
are currently categorized as PPI refractory GERD with their manifestations deemed 
uniform may in fact have heterogeneous etiologies, and therefore a more tailored 
treatment on the basis of each multifaceted pathway is anticipated to resolve their 
symptoms better.
5. Therapeutics
By gaining increasing recognition of these mechanisms, therapeutic possibilities 
could be widened by understanding which individual element is dominant in elicit-
ing GERD symptoms and by diminishing the sensory threshold of what is perceived 
as painful. Several drugs targeting one of these mechanisms are already in phase III 
trials, while others are in a developmental stage.
Since the prostaglandin (PG) E2 receptor, EP1, mediates pain perception 
[70], attempts have been made to reduce PGE2 production or to block EP1 for the 
treatment of GERD symptoms. There are several randomized, placebo-controlled 
crossover studies using diclofenac (reduce PGE2 production), ONO8539, and 
ZD6416 (both EP1 antagonists). Acid induced heartburn was attenuated by 
diclofenac [71], ONO8539 [72], and ZD6416 [73] as compared with a placebo. 
As discussed earlier, TRPV-1 activation in primary afferent neurons evokes the 
sensation of burning pain and induces neurogenic inflammation. Thus the TRPV-1 
antagonist, AZD1386, is expected to reduce responses to noxious stimuli; however, 
the effect has been limited. It was able to increase the pain threshold to heat in 
healthy men [74] but failed to change the threshold in patients with GERD and 
partial PPI responders [75].
Several randomized trials focusing on modulating neurotransmitters or the 
downstream central nervous system have been reported. Pregabalin, a pain modu-
lator including substance P, was able to inhibit the development of acid-induced 
esophageal hypersensitivity [76]. In order to alleviate the central hypersensitiv-
ity, antidepressant nortriptyline was investigated in 20 NERD patients [77]. 
Functional brain imaging by magnetic resonance revealed that nortriptyline was 
found to reduce more significantly brain response to esophageal acid perfusion 
than did placebo. However, this reduction could not improve mental outcome. A 
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randomized controlled trial to investigate the efficacy of antidepressant imipramine 
in patients with esophageal hypersensitivity or functional heartburn is underway 
[NCT01753128].
In an animal study, rikkunshito, a mixture of eight herbal ingredients, was able 
to reduce neuronal activation and peripheral sensitization through the inhibition of 
substance P and CGRP expression [78].
6. Future perspectives
The mechanisms that exert GERD symptoms in patients lacking esophageal 
mucosal injury and/or apparent reflux events remain an area of intense research 
because these patients often show resistance to PPI therapy, and such refractori-
ness compromises patient QOL. There is increasing evidence that multifactorial 
determinants including the number of reflux episodes, the acidity of the refluxate, 
reflux volume, liquid/gas composition, esophageal hypersensitivity, and cognitive 
hypervigilance form a fine network to generate GERD symptoms. Although acid 
is corrosive, the less the roles of acid or mucosal injuries are, the more peripheral 
and central sensitization become important. The advancement of novel diagnostic 
tools focusing on impedance, neuropathophysiology, and psychometrics could 
help identify GERD phenotypes more precisely and practically. These novel 
metrics could also facilitate an understanding that underlying backgrounds of 
GERD are diverse, response to treatment is variable, and mechanistic phenotypes 
are heterogeneous, including hypersensitivity and hypervigilance. Therefore, the 
traditional single approach of focusing solely on acid suppression makes treatment 
results unsatisfactory and problematic. Otherwise, an expanded consideration 
of such multifactorial determinants deserves merit. Each determinant could be 
a potential therapeutic target, and given the wide array of potential therapeutic 
targets, the development of drugs to control each target could therefore increase 
treatment possibilities. Therefore, determining which factors are responsible for 
GERD symptoms on a patient basis can establish more effective and individualized 
treatments, leading to the treatment concept that there is no longer a “one size fits 
all.” This conceptual shift will realize the prescription of tailored, more effective 
drugs as well as the performance of behavioral intervention, and ultimately, fill the 
current therapeutic gaps.
7. Conclusions
The underlying mechanisms of GERD, especially PPI refractory GERD, are mul-
tifactorial. Evidence has been accumulated which supports the concept that GERD 
is established by a cascade starting from cytokine release to central sensitization. 
Since each component could be a therapeutic target, it is important to develop novel 
metrics to quantify the weight of each component and to develop drugs to control 
each component. Clarifying which component is predominant on the patient-by-
patient basis could help realize tailored treatment.
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